## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($133.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Operating cash flow per share of ICU Medical, Inc. â€“ BX:IC7**
- Source: TradingView | 20251208T210952 | Neutral | Relevance: 98%
- This article focuses on the operating cash flow per share for ICU Medical, Inc. (BX:IC7) as presented on TradingView. It provides financial data and a general overview of the company's performance metrics. The content is primarily a data point for investors rather than an analysis.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 17.9x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 17.9 |
| Current P/E | 19.0 |
| YoY Growth | 6.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -0.2% to -2.7% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.66), momentum weakening. RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.71% (CS: 25) | Weak |
| RSI_14 | 58.9 | Neutral |
| MACD Histogram | -0.66 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.112x | Above |
| vs SMA200 | 1.084x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $143.77
- **Stop Loss:** $133.71 (7.0% risk)
- **Target:** $153.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $7,044.73
- **Portfolio %:** 7.04%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*